Today

Icahn Enterprises proposed a tender offer to acquire up to 15 million additional shares of CVR Energy at $17.50 per share.

The NYSE is delisting Farfetch's Class A ordinary shares and will suspend trading immediately due to the company's financial situation and plans to dispose of assets.

Shattuck Labs announced a private placement of common stock and warrants, potentially raising up to $103 million, which will result in significant dilution for existing shareholders.

Novartis' Itvisma® gene therapy for spinal muscular atrophy (SMA) has received FDA approval for children two years and older, teens, and adults, marking a significant expansion of treatment access.

MSP Recovery, Inc.'s appeal against Nasdaq delisting was denied, resulting in the suspension of its common stock from trading on Nasdaq effective December 22, 2025.

Anebulo Pharmaceuticals will voluntarily delist its common stock from Nasdaq and deregister with the SEC, ending its public reporting obligations.

Twin Hospitality Group Inc. will be delisted from Nasdaq, with trading suspended on February 4, 2026, following its Chapter 11 bankruptcy filing.

JE Cleantech Holdings Ltd's 2025 net income surged to SGD3.2 million from SGD32 thousand, primarily due to a SGD4.1 million gain on asset disposition, while revenue grew 5.3% to SGD20.3 million.

POMDOCTOR Ltd's net loss widened by 250.4% to RMB130.9 million in FY2025, with operating cash flow deteriorating to negative RMB148.5 million, raising significant going concern doubts.

EHang Holdings Ltd's FY 2025 revenue decreased 8.4% to RMB418.0 million, while net loss widened 20.2% to RMB276.4 million, and operating cash flow turned negative.

INVO Fertility, Inc. saw Q1 2026 revenue jump 22.2% to $1.98 million and significantly narrowed its net loss by 68.2% to $(5.54) million, yet liquidity concerns persist.

iSpecimen Inc. reported a severe 85.25% drop in Q1 2026 revenue and a 37.20% increase in net loss, prompting a going concern warning due to recurring losses and negative working capital.

Apimeds Pharmaceuticals US, Inc.

ZenaTech's 2025 revenue surged 558% to $12.9M, primarily from its new DaaS segment, but net loss expanded to $(45.2)M due to increased finance, wage, and G&A expenses, with negative operating cash flow.

Nebius Group N.V.

TeraWulf's Q1 2025 results show an 18.9% revenue decrease to $34.4 million and a widened net loss of $61.4 million, primarily due to increased power costs and bitcoin network difficulty, partially offset by strong operating cash flow.

Satellogic's Q1 2026 revenue surged 80.3% to $6.1 million, but net loss dramatically widened to $(118.3) million, primarily due to a non-cash fair value adjustment of financial instruments.

AST SpaceMobile reported a 28.4% increase in Q2 2025 revenue to $1.16 million, but net loss widened to $(99.39) million, primarily due to higher operating expenses and a significant loss on warrant liabilities.

Traws Pharma reported a net income of $9.2 million for FY2025, a significant turnaround from a $166.5 million net loss in FY2024, primarily due to a non-cash change in warrant liability....

Nocera, Inc. reported a 19.9% decrease in annual revenue to $13.6 million for FY2025, while narrowing its net loss by 35.8% to $(2.9) million....